Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in Salt – page 3

330 clinical trials in Salt, Spain across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Salt at a glance
330
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

330 trials in Salt

Open in trial search

Type 2 diabetes mellitus

Recruiting

Efficacy, safety and dose‑response of once‑weekly subcutaneous UBT251 compared with semaglutide in adults with type 2 diabetes

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S

Neoplasm

Recruiting

Phase 1/2 Study of ter-2013-01, imlunestrant, and fulvestrant in patients with solid tumors with AKT/PI3K/PTEN pathway alterations

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Fulvestrant
  • Sponsor:Terremoto Biosciences Inc.

Breast cancer+1

Recruiting

Evaluation of zongertinib, fulvestrant and goserelin acetate in patients with HR‑positive HER2‑negative advanced breast cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Fulvestrant
  • Sponsor:Medica Scientia Innovation Research S.L.

Follicular lymphoma

Recruiting

Study of AZD0486 plus rituximab versus standard chemotherapy drug combination in previously untreated follicular lymphoma patients

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:AstraZeneca AB

Asthma

Recruiting

Efficacy and Safety of Depemokimab for Early Intervention in Adults and Adolescents with Type 2 Asthma at Risk of Exacerbations

Registered drug
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Depemokimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Non-small cell lung cancer

Recruiting

Study of MK-1084 plus durvalumab versus placebo plus durvalumab in patients with locally advanced KRAS G12C‑mutant non‑small cell lung cancer after chemoradiotherapy

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Merck Sharp & Dohme LLC

Myelofibrosis+1

Recruiting

Study of pelabresib (DAK539) plus ruxolitinib versus placebo plus ruxolitinib in adult patients with myelofibrosis who are JAK‑inhibitor‑naive

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Ruxolitinib
  • Sponsor:Novartis Pharma AG

Crohn's disease

Recruiting

A Phase 3b Study of Guselkumab Compared with Risankizumab in Adults with Moderately to Severely Active Crohn’s Disease

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Janssen Cilag International

Asthma

Recruiting

Efficacy and safety of GB-0895 as adjunctive therapy in adults and adolescents with severe uncontrolled asthma (randomized, placebo‑controlled)

Investigational
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:GB-0895
  • Sponsor:Generate Biomedicines Inc.

Non-small cell lung cancer stage III

Recruiting

Pumitamig Versus Durvalumab in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Without Progression After Chemoradiation

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Non-small cell lung cancer stage IV

Recruiting

EIK1001, Pembrolizumab, and Chemotherapy for Stage 4 Non-Small Cell Lung Cancer in Patients with Stage 4 Non-Small Cell Lung Cancer

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Eikon Therapeutics Inc.

Bladder cancer

Recruiting

Durvalumab and Chemotherapy in Adults With Muscle-Invasive Bladder Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Other cities in Spain

The busiest research cities in the country

All 203 cities in Spain

Clinical research in Salt

What the registry says about research in the country

01 Multiple Sclerosis Research

Extensive research focusing on relapsing-remitting multiple sclerosis and its treatment approaches, including comparative studies of novel therapies and established medications.

  • Treatment Comparisons
  • Long-term Safety Studies
  • Disease Progression Management

Multiple innovative therapies are being evaluated to improve patient outcomes and reduce disease progression.

02 Progressive MS Studies

Dedicated research into Primary Progressive Multiple Sclerosis (PPMS), exploring new therapeutic options through targeted treatment approaches.

  • Disability Progression
  • Novel Treatment Mechanisms
  • Long-term Effectiveness

Studies focus on developing treatments to delay disability progression in PPMS patients.

03 Specialized Conditions

Research addressing specific medical conditions including severe primary hand hyperhidrosis and pregnancy-related conditions such as nausea and vomiting.

  • Topical Treatments
  • Pregnancy-related Conditions
  • Quality of Life Improvements

Clinical investigations aim to enhance treatment options and patient comfort across various conditions.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.